SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-012903
Filing Date
2022-12-30
Accepted
2022-12-30 16:48:36
Documents
12
Period of Report
2022-12-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K admp-8k_122822.htm   iXBRL 8-K 30676
  Complete submission text file 0001387131-22-012903.txt   206626

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE admp-20221228.xsd EX-101.SCH 3266
3 XBRL LABEL FILE admp-20221228_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE admp-20221228_pre.xml EX-101.PRE 22385
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_122822_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221502426
SIC: 2834 Pharmaceutical Preparations